Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors

Journal of Nuclear Medicine

Volumn 44, Issue 8, 2003, Pages 1301-1314

  Delgado Bolton, Roberto C ^a   Fernández Pérez, Cristina ^a   González Maté, Alfredo ^a   Carreras, José L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

18F FDG PET; Carcinoma of unknown primary syndrome; Meta analysis; Neoplasms; Unknown primary

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CALCULATION; CANCER DIAGNOSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EVALUATION; HUMAN; INFORMATION RETRIEVAL; LABORATORY DIAGNOSIS; MEDLINE; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; META ANALYSIS; NEOPLASM; REPRODUCIBILITY; SCINTISCANNING;

FALSE NEGATIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141669338     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients J Clin Oncol. 1994;12:1272-1280.
2. Daugaard G. Unknown primary tumours. Cancer Treatment Rev. 1994;20:119-147.
3. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-2103.
4. Leonard RJ, Nystrom JS Diagnostic evaluation of patients with carcinoma of unknown primary tumor site Semin Oncol. 1993;20:244-250.
5. Rege S, Maass A, Chaiken L, et al Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers Cancer. 1994;73:3047-3058.
6. Bohuslavizki KH, Klutmann S, Kröger S, et al FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-822.
7. Lonneux M, Reffad AM. Metastases from unknown primary tumor: PET-FDG as initial diagnostic procedure? Clin Positron Imaging. 2000;3 137-141.
8. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT) Eur J Cancer. 1999,35:1076-1082.
9. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors [abstract]. Clin Positron Imaging. 2000;3:160.
10. 18F-FDG positron emission tomography (PET) in the detection of unknown primary tumors. Hokkaido Igaku Zasshi. 1999,74:249-256.
11. Schipper JH, Schrader M, Arweiler D, Muller S, Sciuk J Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor. HNO. 1996,44:254-257.
12. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors Ann Surg 1999;230:202-206.
13. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer Laryngoscope. 1999;109:880-885.
14. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers Cancer J Sci Am. 1999;5:214-218.
15. Greven KM, Keyes JW Jr, Williams DW III, McGuirt WF, Joyce WT III. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. 1999;86: 114-118.
16. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown primary tumors using positron emission tomography Cancer. 1998;82:1160-1166.
17. Cook DJ, Sackett DL, Spitzer WO. Methodologie guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-analysis. J Clin Epidemiol 1995;48:167-171.
18. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-455.
19. Irwig L, Tosteson ANA, Gatsonts C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667-676.
20. Thacker SB. Meta-analysis: a quantitative approach to research integration. JAMA. 1988;259:1685-1689
21. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
22. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380-387.
23. Grégoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 1995;48:159-163.
24. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts: a meta-analysis. JAMA. 1994;272:158-162.
25. Huebner RH, Park KC, Schepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177-1189
26. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-924.
27. Schelbert HR, Hoh CK, Royal HD, et al Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med. 1998;39:1302-1305.
28. Kent DL, Larson EB. Disease, level of impact, and quality of research methods: three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. Invest Radiol. 1992;27:245-254.
29. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88-94.
30. Thornbury JR, Kido DK, Mushlin AI, Phelps CE, Mooney C, Fryback DG. Increasing the scientific quality of clinical efficacy studies of magnetic resonance imaging. Invest Radiol 1991,26:829-835.
31. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826
32. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293-1316.
33. Fahey MT, Irwig L, Macaskill P. Mesa-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689.
34. 18F-FDG PET [abstract]. Eur J Nucl Med. 2000;27:902.
35. Aassar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999;210:177-181.
36. 18F]- fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123:294-301
37. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? current convictions and controversies JAMA. 1993;269:2749-2753.
38. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987;6:11-29
39. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872.
40. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996,347:363-366.